Disappointing enrollment experiences led Medtronic to suspend its Impasse trial, an angiography study of pelvic anatomy as associated with erectile dysfunction, which was intended to include 350 patients.
Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.
With new and next-generation stents gaining ground over their forebears, the stent wars don’t look to be letting up anytime soon.
The battle continued at the Transcatheter Cardiovascular Therapeutics meeting this week, where pooled results from a pair of studies further affirmed that next-generation drug-eluting stents demonstrate better safety and efficiency at 1 year compared to bare-metal stents.
Researchers combined data from the Examination and Comfortable AMI studies, which comprised a total of more than 2,600 patients, to look for larger trends in the DES vs. BMS battle.
Heading into next week’s Transcatheter Cardiovascular Therapies 2012 conference in Miami, the Natick, Mass.-based medical device company’s global chief medical officer told us that BSX is planning to highlight several technologies at the show.